Headquartered in Toronto, Canada, COSCIENS Biopharma Inc., established in 1990 and rebranded from Aeterna Zentaris Inc. in August 2024, is a life sciences enterprise dedicated to the development and commercialization of specialized products. Serving the cosmeceutical, nutraceutical, and pharmaceutical industries, the company extends its reach across the United States, Germany, Colombia, the United Kingdom, and other global regions. Its operations are divided into two core segments: Active Ingredients and Pharmaceutical. The Active Ingredients portfolio features distinctive compounds such as oat beta glucan, formulated as a chewable aid for cholesterol management; yeast beta glucan, available as a nutraceutical capsule to fortify the immune system; and avenanthramides, a chewable nutraceutical designed to alleviate inflammation for both health and cosmetic applications. In its Pharmaceutical segment, the company highlights Macrilen/Ghryvelin (macimorelin). This orally administered peptidomimetic ghrelin receptor (GHSR-1a) agonist functions by stimulating the secretion of growth hormone upon binding to GHSR-1a. Its primary uses encompass the diagnostic assessment of adult and childhood-onset growth hormone deficiencies, alongside broader applications in endocrinology and oncology. COSCIENS Biopharma markets its offerings through an extensive distribution network. The company maintains strategic licensing agreements with partners including Pharmanovia, MegaPharm Ltd., ER Kim Pharmaceuticals Bulgaria Eood, and NK MEDITECH Ltd., in addition to research collaborations with Agriculture Canada and the University of Alberta.
